Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Ixabepilone and Cyclophosphamide as Neoadjuvant Therapy in HER-2 Negative Breast Cancer

ClinicalTrials.gov ID: NCT00866905

Public ClinicalTrials.gov record NCT00866905. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase II Study of Ixabepilone and Cyclophosphamide as Neoadjuvant Therapy in HER2-Negative Breast Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

We propose to evaluate ixabepilone in combination with cyclophosphamide for the neoadjuvant treatment of locally advanced breast cancer. In this regimen, ixabepilone is substituted for docetaxel, since preclinical and clinical studies suggest that ixabepilone is more active than either docetaxel or paclitaxel. The combination of ixabepilone and cyclophosphamide could further improve the efficacy of non-anthracycline neoadjuvant therapy.

Study identification

NCT ID
NCT00866905
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Enrollment
168 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 31, 2009
Primary completion
Jun 30, 2014
Completion
Sep 30, 2014
Last update posted
Nov 21, 2021

2009 – 2014

United States locations

U.S. sites
20
U.S. states
14
U.S. cities
19
Facility City State ZIP Site status
Aventura Medical Center Aventura Florida 33180
Florida Cancer Specialists Fort Myers Florida 33901
Watson Clinic Center for Cancer Care and Research Lakeland Florida 33805
Medical Oncology Associates of Augusta Augusta Georgia 30901
Northeast Georgia Medical Center Gainesville Georgia 30501
Providence Medical Group Terre Haute Indiana 47802
Mercy Hospital Portland Maine 04101
Center for Cancer and Blood Disorders Bethesda Maryland 20817
National Capital Clinical Research Consortium Bethesda Maryland 20817
St. Louis Cancer Care Chesterfield Missouri 63017
Methodist Cancer Center Omaha Nebraska 68114
Hematology Oncology Associates of Northern NJ Morristown New Jersey 07960
Oncology Hematology Care Cincinnati Ohio 45242
Cancer Centers of Southwest Oklahoma Lawton Oklahoma 73505
South Carolina Oncology Associates, PA Columbia South Carolina 29210
Chattanooga Oncology Hematology Associates Chattanooga Tennessee 37404
Family Cancer Center Collierville Tennessee 38017
Tennessee Oncology Nashville Tennessee 37203
South Texas Oncology and Hematology San Antonio Texas 78258
Virginia Cancer Institute Richmond Virginia 23235

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00866905, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 21, 2021 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00866905 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →